Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00354809
Status:
COMPLETED
Last Update Posted:
2015-04-16
First Post:
2006-07-18
Brief Title:
Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Crossover Study to Evaluate the Effects of Morning Administration of GW679769 10mg and 30 mg on Polysomnograph Sleep Recordings Subjective Sleep Assessment Daytime Cognition and Psychomotor Function in Subjects With Primary Insomnia
Status:
COMPLETED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to determine whether morning doses of GW679769 taken daily for 1 to 9 days will promote sleep during the following night without significant post-dose thinking impairment and drowsiness in subjects with primary insomnia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None